EAST AMHERST, NY, June 16, 2021 /24-7PressRelease/ -- Marquis Who's Who, the world's premier publisher of biographical profiles, is proud to present Dr. Ravindra K. Pandey with the Albert Nelson Marquis Lifetime Achievement Award. An accomplished listee, Dr. Pandey celebrates many years' experience in his professional network, and has been noted for achievements, leadership qualities, and the credentials and successes he has accrued in his field. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Dr. Ravindra K. Pandey, Distinguished Member, Professor of Oncology and Director of Pharmaceutical Chemistry at Roswell Park Center Institute is a trained synthetic medicinal chemist with extensive experience in drug design, drug delivery, molecular recognition, and tumor diagnosis. He was awarded a Ph.D, under Prof. B.C. Joshi, University of Rajasthan, Jaipur, India. From 1980-83 he was a postdoctoral fellow at U.C. Davis, with Prof. K.M. Smith on the synthesis of naturally occurring Porphyrins and supramolecular systems. From 1983-84 he worked in the laboratory of Prof. A.H. Jackson at University College, Cardiff, U.K. on biochemistry of Porphyrins. He spent another two years (1984-86) asd a Research Associate at U.C. Davis with Prof. K.M. Smith on medicinal aspects of porphyrin-based compounds. He then worked on a J&J funded project as a Staff Scientist from 1986-90, before joining Roswell Park Cancer Institute Buffalo in 1990.
After joining Roswell Park Cancer Institute, he has been working on photodynamic therapy and cancer imaging. His research group has also been investigating the utility of certain nanoparticles (ORMOSIL, polycryylamide, gold, rHDL, chitosan and certain polymers) in developing multifunctional platforms. Dr. Pandey received NIH funding in all five cases and his program has been continuously funded by federal and private organizations since 1992.
One of the photosensitizers (HPPH) synthesized in his laboratory is currently undergoing Phase II human clinical trials and two other candidates which show potential for tumor imaging by PET and near infrared (NIR) fluorescence-guided photodynamic therapy (including surgery) are under consideration of US FDA for Phase 1 clinical trials. The current focus of his laboratory is to develop tumor-targeted dual-modality agents, multifunctional biodegradable/biocompatible nanoparticles for imaging and photodynamic therapy (PDT) in combination with other treatment modalities (e.g., surgery and chemotherapy). Efforts are also underway to isolate plant products from Indian and Chinese medicinal plants and investigate their biological efficacy. Dr. Pandey has published 300 research papers, several review articles, book chapters and patents (approved & submitted) to his credit. A Handbook on PDT co-edited by him has been published by World Scientific in May 2016.
He has organized several national international symposiums on PDT and tumor-imaging. He is a member of the Editorial and Advisory Board of several international scientific journals and reviewers of grant proposals of several countries (China, Italy, France, Israel and the United States). Dr. Pandey has received western New York Inventor of the Year awards (several), international award on heterocyclic chemistry, award for the excellence in PDT by the International Society of Porphyrins and Phthalocyanines, the American Chemical Society's Jacob Schoelkopf award and recently China 1000 Talent Scientists Award for his contribution in translational research.
Dr. Pandey is the Founder and Chief Scientific Officer (CSO) of Photolitec, LLC, a spin-off company of Roswell Parl Cancer Institute. His research is "truly" translational, and some of his inventions are already licensed to the pharmaceutical companies located in India, China and the United States. Photolitec, LLC under his leadership has been able to receive several NIH funded peer-reviewed combined Phase I/II SBIR and STTR grants.
Photolitec, LLC has established a joint venture (AMIOCOTHERANOSTICS) located in Buffalo, NY in collaboration with AMI ORGANICS, an India-based company, and has received Orphan Drug Status for two precuts: (1) Photobac: For the treatment of Glioblastoma (brain cancer) and (2) HPPH (Photochlor) for the treatment of esophagus cancer. Dr. Pandey's research is truly translational, and has shown the ability to move the products from bench side.
In recognition of outstanding contributions to his profession and the Marquis Who's Who community, Dr. Pandey has been featured on the Albert Nelson Marquis Lifetime Achievement website. Please visit www.ltachievers.com for more information about this honor.
About Marquis Who's Who®
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® now publishes many Who's Who titles, including Who's Who in America®, Who's Who in the World®, Who's Who in American Law®, Who's Who in Medicine and Healthcare®, Who's Who in Science and Engineering®, and Who's Who in Asia®. Marquis® publications may be visited at the official Marquis Who's Who® website at www.marquiswhoswho.com.
# # #